On Dec. 7, 2020, Moderna announced that the Canadian Government had increased its confirmed order commitment by 20 million doses of Modernaﾒs vaccine candidate against COVID-19, mRNA-1273, bringing its confirmed order commitment to 40 million doses.

Moderna remained on track to be able to start delivery of its COVID-19 vaccine candidate to help protect Canadians following regulatory approval by Canadian health authorities. Moderna could ship its COVID-19 vaccine as soon as December if regulatory approval is granted. The Company had already initiated the rolling review process with Health Canada and intended to seek Prequalification (PQ) and/or Emergency Use Listing (EUL) with the World Health Organization (WHO).

The Canadian vaccine supply was sourced from Moderna’s European production capacity with its strategic manufacturing partner Lonza in Switzerland, and ROVI in Spain for fill-finish services.